163 related articles for article (PubMed ID: 35308569)
1. GLUT1 and ASCT2 Protein Expression in Papillary Thyroid Carcinoma Patients and Relation to Hepatitis C Virus: A Propensity-Score Matched Analysis.
Ibrahiem AT; Fawzy MS; Abdulhakim JA; Toraih EA
Int J Gen Med; 2022; 15():2929-2944. PubMed ID: 35308569
[TBL] [Abstract][Full Text] [Related]
2. GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma.
Sun HW; Yu XJ; Wu WC; Chen J; Shi M; Zheng L; Xu J
PLoS One; 2016; 11(12):e0168907. PubMed ID: 28036362
[TBL] [Abstract][Full Text] [Related]
3. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
4. GLUT1 and ASCT2 expression and their prognostic value in colorectal carcinoma.
Ibrahiem AT; Refat S; Elnaghi K; Emarah Z; Nagib RM
Indian J Pathol Microbiol; 2023 Nov; ():. PubMed ID: 38394402
[TBL] [Abstract][Full Text] [Related]
5. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study.
Schönberger J; Rüschoff J; Grimm D; Marienhagen J; Rümmele P; Meyringer R; Kossmehl P; Hofstaedter F; Eilles C
Thyroid; 2002 Sep; 12(9):747-54. PubMed ID: 12481939
[TBL] [Abstract][Full Text] [Related]
6. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
8. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
9. High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma.
Li WF; Wang G; Zhao ZB; Liu CA
Clin Endocrinol (Oxf); 2015 Oct; 83(4):572-80. PubMed ID: 25418110
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.
Moon SH; Oh YL; Choi JY; Baek CH; Son YI; Jeong HS; Choe YS; Lee KH; Kim BT
Endocr Res; 2013; 38(2):77-84. PubMed ID: 22888973
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of COT is related to recurrence of papillary thyroid cancer.
Lee J; Jeong S; Park JH; Lee CR; Ku CR; Kang SW; Jeong JJ; Nam KH; Shin DY; Lee EJ; Chung WY; Jo YS
Medicine (Baltimore); 2015 Feb; 94(6):e548. PubMed ID: 25674762
[TBL] [Abstract][Full Text] [Related]
12. The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression.
Grabellus F; Worm K; Schmid KW; Sheu SY
Thyroid; 2012 Apr; 22(4):377-82. PubMed ID: 22376167
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma.
Honjo H; Kaira K; Miyazaki T; Yokobori T; Kanai Y; Nagamori S; Oyama T; Asao T; Kuwano H
J Surg Oncol; 2016 Mar; 113(4):381-9. PubMed ID: 26936531
[TBL] [Abstract][Full Text] [Related]
14. Tissue microRNA-182 expression level and its potential prognostic value for papillary thyroid carcinoma.
Yao XG; Tan Q; Liu PP; Feng LJ
Int J Clin Exp Pathol; 2019; 12(8):3128-3133. PubMed ID: 31934155
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis.
Liu X; Su C; Xu J; Zhou D; Yan H; Li W; Chen G; Zhang N; Xu D; Hu H
Oncol Lett; 2019 Feb; 17(2):2308-2316. PubMed ID: 30675296
[TBL] [Abstract][Full Text] [Related]
16. Expression of glutamine metabolism-related proteins in thyroid cancer.
Kim HM; Lee YK; Koo JS
Oncotarget; 2016 Aug; 7(33):53628-53641. PubMed ID: 27447554
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of extranodal extension in papillary thyroid carcinomas: A propensity score matching analysis and proposal for incorporation into current tumor, lymph node, metastasis staging.
Genpeng L; Pan Z; Tao W; Rixiang G; Jingqiang Z; Zhihui L; Jianyong L
Surgery; 2022 Feb; 171(2):368-376. PubMed ID: 34482990
[TBL] [Abstract][Full Text] [Related]
18. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
[TBL] [Abstract][Full Text] [Related]
20. Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.
Lee SJ; Choi KC; Han JP; Park YE; Choi MG
J Endocrinol Invest; 2007 Jan; 30(1):28-34. PubMed ID: 17318019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
